about
Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor MicroenvironmentPhenotypic T cell exhaustion in a murine model of bacterial infection in the setting of pre-existing malignancyTargeting microenvironment in cancer therapeuticsImmunological battlefield in gastric cancer and role of immunotherapiesPhase I dendritic cell p53 peptide vaccine for head and neck cancer.Immunotherapy as a Potential Treatment for Chordoma: a Review.Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysisImmunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.Murine lung cancer induces generalized T-cell exhaustion.The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastrointestinal tract cancer: a systematic review and meta-analysisHLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisitionHelicobacter Pylori Promote B7-H1 Expression by Suppressing miR-152 and miR-200b in Gastric Cancer CellsMolecular targeting of liposomal nanoparticles to tumor microenvironment.Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.The tumor microenvironment and its role in promoting tumor growth.Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemiaImmune responses to malignancies.Head and neck squamous carcinomas with exophytic and endophytic type of growth have the same prognosis after surgery and adjuvant radiotherapy.Twist and miR-34a are involved in the generation of tumor-educated myeloid-derived suppressor cells.Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma.Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia.Targeting human inducible regulatory T cells (Tr1) in patients with cancer: blocking of adenosine-prostaglandin E₂ cooperation.The role of the adenosinergic pathway in immunosuppression mediated by human regulatory T cells (Treg).What are regulatory T cells (Treg) regulating in cancer and why?Therapeutic cancer vaccines: a long and winding road to success.Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcomeHuman leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma.Enhanced Suppressive Activity of Regulatory T Cells in the Microenvironment of Malignant Pleural Effusions.
P2860
Q26745898-4007A4F7-CE0C-4E61-BB7F-9FB3A6356CA4Q27346770-26811E60-381B-4117-9BC2-F2B120123592Q28067219-8C095DE1-F997-4EBA-BFF8-30292A678EF7Q28071836-A652D3FF-E72F-4A8D-B501-BD391A458FF4Q30577847-D01E70DE-B1C6-4E91-8289-FF3CDA59B40AQ33276143-39D32377-F052-4B70-BA66-8B5B712C28CBQ33903025-13DC1BB2-06EF-4ED0-9AC2-ED402CD31B93Q34170003-0AC5912E-4207-4DC3-BEDB-034CE63800B4Q34981971-73BD7D2E-9D81-4492-AC79-9F5ABDA62ABDQ35562860-551F4DDB-6B4B-4997-B681-4EA22E151701Q36116591-74857B69-E683-4784-9146-23B94621304FQ36184954-1F0FB9D0-01EF-427D-88DF-1E78D7C9FE7AQ36240460-3C6DFA7D-BD3B-47C0-A40D-4AED0099DCCDQ36500108-4FEACB19-6D9D-4DFB-8E17-7169D163FC22Q36539682-E928877A-B311-4D3B-B34F-CEC60C76633DQ36946019-B9403A5F-71E6-496F-A34C-69E5E9267EC3Q36979119-A423906A-F313-40CE-899C-AEFEEFDB7FA7Q37040501-CCB5D59F-779F-4F50-8677-3AC7354AFD3CQ37281368-873117C2-7CFC-47B8-AE92-84CEE0E79A6EQ37291308-4642201F-784D-4422-94E1-7F31FEE9CF36Q37294991-7CB1CFD8-8F82-498C-AF33-ED33BA92C60EQ37645126-AB5D06BE-4EC3-404B-BE56-B65AF7FCAF71Q37894107-93AC8A1B-C51E-47BE-B2A1-1E2AD7E852BAQ37956691-0A629759-C5CC-464D-A786-926288834305Q37998754-06E377BB-8F8F-4715-A409-2BABAE96E6F1Q38162261-DA56D2F2-CBBB-4361-874E-D2179BA6BEA1Q38515225-126CE5FB-8BC5-4FA3-A6DA-D3687DFB4539Q38952717-63F44C4C-5EDD-4953-ACF1-F18DD77EC418Q41110505-939E3184-5CC4-45A7-8C9F-BC4F2BFA049EQ42110899-CB952584-7778-4A9D-A783-367B7999BDC9Q45061505-C93C8487-6E08-4A98-A0F9-02F0D0A86A4EQ55343231-6CBCFA43-230A-49DE-9A51-EA2CA1C93B36
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor microenvironment and immune escape.
@en
Tumor microenvironment and immune escape.
@nl
type
label
Tumor microenvironment and immune escape.
@en
Tumor microenvironment and immune escape.
@nl
prefLabel
Tumor microenvironment and immune escape.
@en
Tumor microenvironment and immune escape.
@nl
P1476
Tumor microenvironment and immune escape.
@en
P2093
Soldano Ferrone
Theresa L Whiteside
P304
755-74, viii
P356
10.1016/J.SOC.2007.08.004
P577
2007-10-01T00:00:00Z